Zai Lab Ltd. has outlined its strategic priorities and plans for 2026, focusing on advancing its dual-engine model that integrates a commercially scaling business in China with a global innovation engine. The company plans to progress multiple high-impact milestones across its global pipeline, including the continued execution of Zoci’s Phase 3 program and the advancement of novel oncology and immunology assets into clinical development. Additional goals include several anticipated IND filings and data readouts to further validate its integrated R&D platform. Zai Lab also expects to launch COBENFY and continue expanding its existing product franchises, aiming to strengthen its financial foundation and support continued global growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113130363) on January 13, 2026, and is solely responsible for the information contained therein.